Patents Assigned to Medicinal Genomics Corporation
  • Publication number: 20220098637
    Abstract: A method for determining a level of one or more live microbes in a sample of a Cannabis plant includes (a) introducing a DNase enzyme into a sample including (i) Cannabis plant matrix derived from lysed cells of a Cannabis plant and (ii) live microbial cells including microbial genomic DNA, (b) introducing an anionic detergent into the sample, where the anionic detergent is in an amount effective to inactivate the DNase enzyme in the sample and lyse the live microbial cells in the sample, (c) introducing a known quantity of control DNA into the sample, (d) contacting the sample with a plurality of polynucleotide capture agents, (e) isolating the plurality of polynucleotide capture agents, thereby isolating polynucleotides from the microbial genomic DNA and/or control DNA in the sample, and (f) amplifying at least a portion of polynucleotides from the microbial genomic DNA isolated in step (e).
    Type: Application
    Filed: March 26, 2020
    Publication date: March 31, 2022
    Applicant: MEDICINAL GENOMICS CORPORATION
    Inventors: Kevin J. MCKERNAN, Yvonne HELBERT, Heather EBLING
  • Publication number: 20220017974
    Abstract: The present disclosure provides methods and kits for characterizing Cannabis plants. Methods and kits of the present disclosure include detection/amplification of one or more enzymes involved in the production of cannabinoids, such as, for example, tetrahydrocannabinolic acid (THCA) synthase and/or cannabidiolic acid (CBDA) synthase.
    Type: Application
    Filed: June 14, 2021
    Publication date: January 20, 2022
    Applicant: MEDICINAL GENOMICS CORPORATION
    Inventor: Kevin MCKERNAN
  • Patent number: 11035010
    Abstract: The present disclosure provides methods and kits for characterizing Cannabis plants. Methods and kits of the present disclosure include detection/amplification of one or more enzymes involved in the production of cannabinoids, such as, for example, tetrahydrocannabinolic acid (THCA) synthase and/or cannabidiolic acid (CBDA) synthase.
    Type: Grant
    Filed: December 14, 2018
    Date of Patent: June 15, 2021
    Assignee: MEDICINAL GENOMICS CORPORATION
    Inventor: Kevin J. McKernan
  • Publication number: 20140057251
    Abstract: Using the efficiency of next generation sequencing, a draft de novo reference sequence for the Cannabis (C.) Sativa and C. Indica genomes has been generated as well as four full length contiguous sequences with homology to THCA and CBDA synthases and 10 partially homologous contigs with truncated ORFs. In particular aspects the invention is directed to an (one or more) isolated sequence (e.g., nucleic acid sequence, DNA, RNA, genomic sequence, polypeptide) of a Cannabis genome and uses thereof.
    Type: Application
    Filed: August 17, 2012
    Publication date: February 27, 2014
    Applicant: Medicinal Genomics Corporation
    Inventor: Kevin McKernan